| 2.06 -0.08 (-3.74%) | 12-05 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.67 | 1-year : | 3.12 |
| Resists | First : | 2.28 | Second : | 2.67 |
| Pivot price | 1.94 |
|||
| Supports | First : | 1.83 | Second : | 1.55 |
| MAs | MA(5) : | 2.02 |
MA(20) : | 1.89 |
| MA(100) : | 1.77 |
MA(250) : | 0 | |
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 69.4 |
D(3) : | 62.2 |
| RSI | RSI(14): 58.6  |
|||
| 52-week | High : | 15.64 | Low : | 1.1 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ GRI ] has closed below upper band by 25.7%. Bollinger Bands are 2.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.17 - 2.18 | 2.18 - 2.2 |
| Low: | 1.99 - 2 | 2 - 2.01 |
| Close: | 2.08 - 2.1 | 2.1 - 2.12 |
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
Tue, 02 Dec 2025
GRI Bio receives Nasdaq notice for non-compliance with equity listing rule - Investing.com
Fri, 14 Nov 2025
Form 424B3 GRI Bio, Inc. - StreetInsider
Fri, 14 Nov 2025
GRI: Net loss rose to $9.3M YTD; cash runway extends into Q1 2026, but funding uncertainty remains - TradingView
Thu, 18 Sep 2025
GRI Bio Eyes Topline Data For IPF Drug GRI-0621 Following Encouraging Interim Results - RTTNews
Thu, 11 Sep 2025
Will GRI Bio’s Stock Rise After Innovative Unveiling? - timothysykes.com
Thu, 11 Sep 2025
GRI Bio Reports 6-Week Interim Lung Function Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”) - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 3 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 4.1 (%) |
| Shares Short | 120 (K) |
| Shares Short P.Month | 248 (K) |
| EPS | 17.17 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.61 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -137.6 % |
| Return on Equity (ttm) | -397.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.45 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | 0.12 |
| PEG Ratio | 0 |
| Price to Book value | 3.44 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.75 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|